Kidney cancer drugs equal in prolonging survival - 21 News Now, More Local News for Youngstown, Ohio -

Kidney cancer drugs equal in prolonging survival

Updated: Aug 22, 2013 10:05 AM
© iStockphoto.com © iStockphoto.com
  • More NewsMore>>

  • Themes for WaterFire Sharon announced

    Themes for WaterFire Sharon announced

    SHARON, Pa. - WaterFire Sharon will return this summer to the Shenango River. The three big events will have several themes.  The theme on July 19th will be "Elements", August 23rd's theme will be "Origins"More >>
    SHARON, Pa. - WaterFire Sharon will return this summer to the Shenango River. The three big events will have several themes.  The theme on July 19th will be "Elements", August 23rd's theme will be "Origins"More >>
  • Hundreds expected to help with clean up of Dave Grohl Alley

    Hundreds expected to help with clean up of Dave Grohl Alley

    WARREN, Ohio - Hundreds are expected to show up in Warren on Saturday to take part in clean-up effort, after a vandal was caught on camera damaging a tribute to a Warren-born musician.From noon until 4More >>
    WARREN, Ohio - Hundreds are expected to show up in Warren on Saturday to take part in a clean-up effort, after a vandal was caught on camera damaging a tribute to a Warren-born musician.More >>
  • Motorists reminded of more Amish buggies on the roads

    Motorists reminded of more Amish buggies on the roads

    LISBON, Ohio - Orange barrels won't be the only thing motorists will have to watch for while traveling throughout Columbiana County.  Vehicles are often using the same lanes as Amish buggies and localMore >>
    LISBON, Ohio - Orange barrels won't be the only thing motorists will have to watch for while traveling throughout Columbiana County.More >>
By Steven Reinberg
HealthDay Reporter

THURSDAY, Aug. 22 (HealthDay News) -- The drug pazopanib (Votrient) works as well as sunitinib (Sutent) for treating advanced kidney cancer, but it has milder side effects, a new study finds.

Although both drugs are approved by the U.S. Food and Drug Administration as first-line treatments for kidney cancer and both boost survival, pazopanib had the edge in improving the quality of life, the researchers reported.

"Kidney cancer has long been considered one of the most difficult-to-treat cancers, and is associated with a poor prognosis when it's metastasized [or spreading]," said lead researcher Dr. Robert Motzer, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City.

Now there are drugs that attack a gene that is responsible for turning kidney cells into cancer cells, he said. "There has been tremendous progress in the treatment of this disease since 2005 with these targeted drugs," Motzer said. "The first of these drugs was sunitinib, which is considered the standard in first-line treatment for kidney cancer."

This new trial was a head-to-head comparison of sunitinib and pazopanib. The researchers found both had a similar safety profile and survival benefit, but there were milder side effects with pazopanib, Motzer said. These included less fatigue and fewer sores on the bottom of the feet, he noted.

"The data also suggest that patients on pazopanib have a better quality of life than patients on sunitinib," Motzer said. Both drugs cost about the same -- about $6,500 a month -- and are covered by Medicare and many private insurers.

"Both these drugs are good options for first-line treatment," Motzer said. "They allow for us to individualize treatment for patients. In my own practice, I have changed my preferred drug from sunitinib over to pazopanib, because most patients appear to have a better quality of life with pazopanib compared with sunitinib."

The trial was paid for by GlaxoSmithKline Pharmaceuticals, the maker of pazopanib.

Dr. Jessica Kreshover, a urologist at North Shore-LIJ's Arthur Smith Institute for Urology in Lake Success, N.Y., said that "this study shows that there is more than one option for first-line therapy for renal [kidney] cancer."

According to Motzer, 65,000 people are diagnosed with kidney cancer each year in the United States. "It's the sixth most common cancer," he said. And because it is often diagnosed late, 30 percent to 50 percent of the patients develop metastasis, he added. "It's one of the top 10 cancer killers," he noted.

The report was published in the Aug. 22 issue of the New England Journal of Medicine.

"We now have a number of treatment options for kidney cancer," said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. "The question then becomes how do you make a choice."

Lichtenfeld noted that not only did the study show that the drugs had similar survival benefits and that pazopanib was better at improving patients' quality of life, but also that pazopanib saved health care dollars by cutting the number of doctor visits.

"We need to look at our treatments not only in terms of whether they delay the progression of the cancer or increase overall survival, but also what is the cost to the patient and the medical care system," Lichtenfeld said.

For the study, Motzer's team randomly assigned more than 1,100 patients with advanced kidney cancer to either sunitinib or pazopanib.

The investigators found both drugs fared as well in the length of time they held the cancer at bay and extended life -- about nine months.

The real difference was seen in their side effects. Patients taking pazopanib suffered less fatigue, fewer sores on the hands and feet, and fewer bouts of a blood disease called thrombocytopenia, which can cause bleeding, than patients taking sunitinib, Motzer's group found.

Some patients taking pazopanib, however, had higher levels of an enzyme called alanine aminotransferase -- a sign of potential liver damage -- than those taking sunitinib, the researchers noted.

Most importantly, according to Motzer, patients taking pazopanib rated their quality of life better than patients taking sunitinib.

More information

For more on kidney cancer, visit the American Cancer Society.

Copyright © 2013 HealthDay. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
  • Around the WebMore>>

  • Ohio teacher fired over comment on black president

    Ohio teacher fired over comment on black president

    CINCINNATI (AP) - An Ohio teacher has been fired following allegations that he told a black student who said he wanted to become president that the nation didn't need another black president.The Cincinnati Enquirer reports (http://cin.ci/1kIkFmQ ) the Fairfield Board of Education voted 4-0 on Thursday to fire science teacher Gil Voigt.Voigt didn't immediately return a call for comment Friday but has said the student misquoted him.Voigt, who is white, says what he actually told the teen was th...More >>
    CINCINNATI (AP) - An Ohio teacher has been fired following allegations that he told a black student who said he wanted to become president that the nation didn't need another black president.The Cincinnati Enquirer reports (http://cin.ci/1kIkFmQ ) the Fairfield Board of Education voted 4-0 on Thursday to fire science teacher Gil Voigt.Voigt didn't immediately return a call for comment Friday but has said the student misquoted him.Voigt, who is white, says what he actually told the teen was th...More >>
  • 13-1/2 pound boy born at southeastern Pa. hospital

    13-1/2 pound boy born at southeastern Pa. hospital

    Saturday, April 19 2014 8:54 PM EDT2014-04-20 00:54:06 GMT
    DREXEL HILL, Pa. (AP) - A woman has given birth to a more than 13-pound baby at a southeastern Pennsylvania hospital.Officials at Delaware County Memorial Hospital say Brian and Danielle Dwyer's son born Monday is the largest baby they can recall there.Waldo James Mysterious Dwyer tipped the scales at 13 pounds, 8-1/2 ounces.The couple loved the "Where's Waldo?" books as children, so that's where they got their son's first name.Brian Dwyer said the middle name Mysterious is because Waldo was ...More >>
    DREXEL HILL, Pa. (AP) - A woman has given birth to a more than 13-pound baby at a southeastern Pennsylvania hospital.Officials at Delaware County Memorial Hospital say Brian and Danielle Dwyer's son born Monday is the largest baby they can recall there.Waldo James Mysterious Dwyer tipped the scales at 13 pounds, 8-1/2 ounces.The couple loved the "Where's Waldo?" books as children, so that's where they got their son's first name.Brian Dwyer said the middle name Mysterious is because Waldo was ...More >>
  • Teen suspended for asking Miss America to prom

    Teen suspended for asking Miss America to prom

    Saturday, April 19 2014 8:44 PM EDT2014-04-20 00:44:23 GMT
    YORK, Pa. (AP) - A Pennsylvania high school student is in hot water for asking Miss America to prom during a question and answer session at school.Eighteen-year-old Patrick Farves said he received three days of in-school suspension Thursday because he asked Nina Davuluri to prom.The senior at Central York High School stood up and popped the prom question, then walked to the stage with a plastic flower. Davuluri just laughed and the students cheered.School officials heard about Farves' plan in...More >>
    YORK, Pa. (AP) - A Pennsylvania high school student is in hot water for asking Miss America to prom during a question and answer session at school.Eighteen-year-old Patrick Farves said he received three days of in-school suspension Thursday because he asked Nina Davuluri to prom.The senior at Central York High School stood up and popped the prom question, then walked to the stage with a plastic flower. Davuluri just laughed and the students cheered.School officials heard about Farves' plan in...More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 Worldnow and WFMJ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms